[go: up one dir, main page]

MX2018015119A - Particulas de nicotina. - Google Patents

Particulas de nicotina.

Info

Publication number
MX2018015119A
MX2018015119A MX2018015119A MX2018015119A MX2018015119A MX 2018015119 A MX2018015119 A MX 2018015119A MX 2018015119 A MX2018015119 A MX 2018015119A MX 2018015119 A MX2018015119 A MX 2018015119A MX 2018015119 A MX2018015119 A MX 2018015119A
Authority
MX
Mexico
Prior art keywords
particles
nicotine particles
liquid mixture
nicotine
liquid
Prior art date
Application number
MX2018015119A
Other languages
English (en)
Other versions
MX387520B (es
Inventor
VOLPE Nicolo
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of MX2018015119A publication Critical patent/MX2018015119A/es
Publication of MX387520B publication Critical patent/MX387520B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método incluye combinar nicotina con un líquido portador para formar una mezcla líquida y secar por atomizado la mezcla líquida para formar una primera pluralidad de partículas. La primera pluralidad de partículas se mueles para formar una segunda pluralidad de partículas.
MX2018015119A 2016-06-30 2017-06-21 Particulas de nicotina. MX387520B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177156 2016-06-30
PCT/IB2017/053710 WO2018002779A1 (en) 2016-06-30 2017-06-21 Nicotine particles

Publications (2)

Publication Number Publication Date
MX2018015119A true MX2018015119A (es) 2019-04-15
MX387520B MX387520B (es) 2025-03-18

Family

ID=56296658

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015119A MX387520B (es) 2016-06-30 2017-06-21 Particulas de nicotina.

Country Status (18)

Country Link
US (2) US11458093B2 (es)
EP (1) EP3478265B1 (es)
JP (2) JP7471774B2 (es)
KR (1) KR102559152B1 (es)
CN (1) CN109310623B (es)
AU (1) AU2017290610A1 (es)
BR (1) BR112018075017A2 (es)
CA (1) CA3023626A1 (es)
ES (1) ES3005760T3 (es)
IL (1) IL263340A (es)
MX (1) MX387520B (es)
PH (1) PH12018502715A1 (es)
PL (1) PL3478265T3 (es)
RU (1) RU2741309C2 (es)
SG (1) SG11201809630RA (es)
UA (1) UA126853C2 (es)
WO (1) WO2018002779A1 (es)
ZA (1) ZA201807080B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524648A (ja) * 2016-06-30 2019-09-05 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子および組成物
CN110300588A (zh) * 2017-03-07 2019-10-01 菲利普莫里斯生产公司 可吸入尼古丁调配物及其制造和使用方法
US20220395015A1 (en) 2019-11-14 2022-12-15 Philip Morris Products S.A. Improved tobacco flavoured dry powder formulation
PL4164595T3 (pl) * 2020-06-15 2025-11-24 Philip Morris Products S.A. Kompozycje proszku anatabiny
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物
IL300741A (en) * 2020-09-03 2023-04-01 Philip Morris Products Sa Active powder compositions with low hygroscopicity
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US12295412B2 (en) 2022-01-28 2025-05-13 Altria Client Services Llc Oral pouch product
CN120417888A (zh) * 2022-10-27 2025-08-01 韩国烟草人参公社 用于吸入的尼古丁干粉的制备方法
CN120500327A (zh) * 2022-10-27 2025-08-15 韩国烟草人参公社 用于吸入的低剂量尼古丁干粉组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4655231A (en) 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
JP3388896B2 (ja) * 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
CA2231968A1 (en) 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US20120042886A1 (en) 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US20080138398A1 (en) 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
FI20060428A7 (fi) 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
US20080286340A1 (en) 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
CA2744655A1 (en) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
PL2435024T3 (pl) 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
SE536491C2 (sv) 2012-03-26 2013-12-27 Bionicotine Ab Påse innehållande nikotin och en tuggummikomposition
WO2014150245A1 (en) 2013-03-15 2014-09-25 Aradigm Corporation Methods for inhalation of smoke-free nicotine
ITMI20130572A1 (it) 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
MX384606B (es) 2013-05-06 2025-03-12 Juul Labs Inc Formulaciones de sal de nicotina para dispositivos de aerosol y métodos de los mismos.
CA2944471C (en) 2014-04-08 2020-03-31 Sansa Corporation (Barbados) Inc. Nicotine formulations and methods of making the same
RU2680422C2 (ru) * 2014-04-28 2019-02-21 Филип Моррис Продактс С.А. Ингалятор ароматизированного никотинового порошка

Also Published As

Publication number Publication date
ZA201807080B (en) 2019-07-31
PL3478265T3 (pl) 2025-04-14
US12048762B2 (en) 2024-07-30
KR102559152B1 (ko) 2023-07-26
WO2018002779A1 (en) 2018-01-04
US11458093B2 (en) 2022-10-04
BR112018075017A2 (pt) 2019-03-19
CN109310623A (zh) 2019-02-05
US20190117567A1 (en) 2019-04-25
EP3478265A1 (en) 2019-05-08
ES3005760T3 (en) 2025-03-17
AU2017290610A1 (en) 2018-11-15
EP3478265B1 (en) 2025-01-01
JP2022116082A (ja) 2022-08-09
KR20190026655A (ko) 2019-03-13
RU2018144108A (ru) 2020-07-30
PH12018502715A1 (en) 2019-07-29
IL263340A (en) 2018-12-31
JP7583764B2 (ja) 2024-11-14
JP2019519542A (ja) 2019-07-11
UA126853C2 (uk) 2023-02-15
US20230000767A1 (en) 2023-01-05
RU2018144108A3 (es) 2020-07-30
CA3023626A1 (en) 2018-01-04
CN109310623B (zh) 2022-10-21
EP3478265C0 (en) 2025-01-01
SG11201809630RA (en) 2018-11-29
RU2741309C2 (ru) 2021-01-25
MX387520B (es) 2025-03-18
JP7471774B2 (ja) 2024-04-22

Similar Documents

Publication Publication Date Title
MX2018015119A (es) Particulas de nicotina.
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
MX2018003629A (es) Anticuerpos anti-pd1 y metodos de uso.
EP3672764A4 (en) HIGH-SPEED HANDLING OF NON-UNIFORM OBJECTS
TWD190312S (zh) 項鍊
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
CL2018003282A1 (es) Métodos y composiciones para el tratamiento de cánceres resistentes a los inhibidores de la vía no erk mapk
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
TWD182272S (zh) 項鍊
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2015002239A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
PL3215133T3 (pl) Sposoby i kompozycje związane z zastosowaniem związków powierzchniowo czynnych o niskiej hlb do wytwarzania syntetycznych nanonośników zawierających rapalog
TWD181261S (zh) 項鍊
TWD178825S (zh) 項鍊
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
TWD176022S (zh) 項鍊
MX2015017366A (es) Formulacion de perlas de cisteamina de liberacion retardada.
EP3731832A4 (en) CANNABINOID DOSAGE FORM
MX377774B (es) Formulaciones de proteinas.
MX2017013881A (es) Composiciones y metodos para la vigilancia activa del cancer de prostata.
MX2017000526A (es) Formulaciones de anticuerpos cristalinos.
AR104360A1 (es) Formas de sal y formas cristalinas farmacéuticas
EP3448432A4 (en) TARGETED ADMINISTRATION OF AEROSOLS OF MAGNETIZED ACTIVE AGENTS